330862-38-9

Upstream product

• 122-51-0 orthoformic acid triethyl ester 
• 330194-34-8 (1'S,2R)-4-oxo-1-(1'-phenylethyl)-piperidine-2-carboxylic acid ethyl ester 
• 64-17-5 ethanol 
• 330194-35-9 (1'S,2S)-4-oxo-1-(1'-phenylethyl)-piperidine-2-carboxylic acid ethyl ester 
• 2627-86-3 (S)-1-phenyl-ethylamine 

Downstream Products

• 500688-86-8 biphenyl-4-carboxylic acid N-[(1'S,2R)-4,4-diethoxy-1-(1'-phenylethyl)piperidin-2-ylmethyl]amide 
• 330194-37-1 (1'S,2R)-4,4-diethoxy-1-(1'-phenylethyl)-2-phthalimidomethyl-piperidine 
• 330194-38-2 (1'S,2R)-4,4-diethoxy-1-(1'-phenylethyl)-2-aminomethyl-piperidine 
• 330862-39-0 (1'S,2R)-4,4-diethoxy-1-(1'-phenylethyl)-2-hydroxymethyl-piperidine 

Relevant academic research and scientific papers

ANTIBACTERIAL QUINOLINE DERIVATIVES

The present invention relates to novel substituted quinoline derivatives according to the general Formula (Ia) or Formula (Ib): including any stereochemically isomeric form thereof, a pharmaceutically acceptable salt thereof, a N-oxide form thereof or a s

ANTIBACTERIAL QUINOLINE DERIVATIVES

The present invention relates to novel substituted quinoline derivatives according to the general Formula (Ia) or Formula (Ib): including any stereochemically isomeric form thereof, a pharmaceutically acceptable salt thereof, a N-oxide form thereof or a solvate thereof. The claimed compounds are useful for the treatment of a bacterial infection. Also claimed is a composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of the claimed compounds, the use of the claimed compounds or compositions for the manufacture of a medicament for the treatment of a bacterial infection and a process for preparing the claimed compounds.

Method of inhibiting protein tyrosine phosphatase 1B and/or T-cell protein tyrosine phosphatase 4 and/or other PTPases with an Asp residue at position 48

The present invention provides a method of inhibiting a member of a family of Protein Tyrosine Phosphatases (PTPases, PTPs) such as PTP1B, TC-PTP, CD45, SHP-1, SHP-2, PTPα, PTPε, PTPμ, PTPδ, PTPσ, PTPζ, PTPβ, PTPD1, PTPD2, PTPH1, PTP-MEG1, PTP-LAR, and HePTP by exposing said Ptpase member by administration to a host or otherwise to at least one compound with certain structural, physical and spatial characteristics that allow for the interaction of said compound with specific residues of the active site of PTP1B and/or TC-PTP. These compounds are indicated in the management or treatment of a broad range of diseases such as autoimmune diseases, acute and chronic inflammation, osteoporosis, various forms of cancer and malignant diseases, and type I diabetes and type II diabetes, as well as in the isolation of PTPases and in elucidation or further elucidation of their biological function.

A convenient large-scale chiral synthesis of protected 2-substituted 4-oxo-piperidine derivatives

A convenient large-scale chiral synthesis of protected 2-substituted-4-oxo-piperidine derivatives is described. Hetero Diels-Alder reaction between trifluoroacetic acid-boron trifluoride activated (1-phenyl-ethylimino)acetic acid ethyl ester and 2-trimeth